Toronto, Ontario, Canada, 5 September 2016 – BresoTec has entered into an exclusive distribution agreement with Intus Healthcare to launch BresoDx® in the UK. This marks the European launch of BresoDx®, the first cordless, single-user, home sleep test used as an aid in the diagnosis of sleep apnoea.
“We are delighted to make BresoDx® available to patients and consultants in the UK. This is the first step on our journey of global commercialisation and reach” says Julie Brogren, Chief Operating Officer and VP of Global Sales and Marketing. “Intus is an ideal partner in the UK. Intus has many years’ experience and a strong network in the field and we share the belief that there is a need for a reliable, simple and cost-effective device for diagnosing sleep apnoea”. Intus Healthcare has gained the exclusive rights for the marketing, distribution and sale of BresoDx® in the UK. “BresoDx® makes the diagnosis of sleep apnoea easy and accessible to more people. It is well validated and has a 95% correlation with the results of a traditional in-lab (PSG) sleep study” says Martin Heller, Managing Director of Intus Healthcare. “We are excited to be present at the European Respiratory Society’s Congress (ERS) with BresoTec to launch BresoDx®”.
BresoTec Inc., a Canadian company based in Toronto, Ontario, develops, manufactures and sells products for the diagnosis and treatment of sleep disorders. BresoTec’s first product, BresoDx®, is an innovative device using breath sound and movement recording technology to aid in the diagnosis of sleep apnoea. It is the world’s first cordless, single-user, home sleep testing device for this purpose. The accuracy of BresoDx®versus the in-lab standard test for detecting sleep apnoea (polysomnography) has been validated in several clinical trials led by Drs. Hisham Alshaer and Douglas Bradley of the University Health Network. Such accuracy in a simple, cordless device establishes BresoDx® as a reliable, cost- effective and user-friendly home sleep test for consultants, patients and health care providers.
BresoDx® received regulatory approval from Health Canada in December 2014 and from the European Commission (CE marking) in February 2016.
The technology behind BresoDx® was developed by iDAPT Research at Toronto Rehabilitation Institute, iDAPT Research is the leading rehabilitation research center in the world. Toronto Rehabilitation Institute is a part of University Health Network (UHN) and is fully affiliated with the University of Toronto. BresoTec was founded by UHN and MaRS Innovation, a non-profit incubator that acts on behalf of 14 of Toronto’s top universities, institutions and research institutes, as well as the MaRS Discovery District. BresoTec’s technology is exclusively licensed from UHN.
About Intus Healthcare
Intus Healthcare founded in 2004, specialises in sleep disorders, specifically Sleep Disordered Breathing (SDB). Intus Healthcare have been helping people with SDB for many years with almost all the major brands around the world. Intus supplies both the NHS and private patients across 35+ different countries from their UK base.
About sleep apnoea
Sleep apnoea is a condition characterised by repetitive cessations of breathing during sleep that disrupt sleep and cause excessive daytime sleepiness. It affects around 10% of the adult population globally. It is treatable, but less than 15% of North Americans with the condition have been diagnosed; fewer elsewhere. Left untreated, sleep apnoea leads to serious health complications, including a 3–4 fold increase in the risk of hypertension, stroke and heart failure.Untreated sleep apnoea is also strongly associated with an increased risk of traffic accidents due to sleepiness.
The low rate of diagnosis is mainly due to the substantial cost and inconvenience of undergoing overnight testing in a sleep laboratory. This complex in-lab test is called polysomnography (PSG). BresoDx® is designed to meet the need for reliable, less costly and simpler means of diagnosing sleep apnoea.